Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology • Medical Oncology • Her2+ • Breast Cancer, Metastatic • Breast Cancer, Non-metastatic • tnbc • Metastatic HR+ Breast Cancer • ASTRO 2024
What are your top takeaways in Breast Cancer from ASTRO 2024?
Answer from: Radiation Oncologist at Academic Institution
There were a number of important presentations on breast cancer at the ASTRO 2024 meeting. The three randomized trial discussed below stood out.1. Abstract 1: Poppe MM, et al.: A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHA...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
RT CHARM: Dr. @Poppe's presentation regarding the RT CHARM trial of conventional fraction PMRT vs moderately hypofractionated PMRT revealed that hypofractionated PMRT is safe, effective, and non-inferior to conventional fractionation among patients who undergo reconstruction. This large, random...
Answer from: Radiation Oncologist at Community Practice
From the Plenary Session Monday 1:30 pm: A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505) presented by Dr. @Matthew Poppe. I have been slow on the uptake with moderate hypofractionation in the post-mastec...
Answer from: Radiation Oncologist at Academic Institution
Hypofractionated radiotherapy should be considered the standard of care for most patients with breast cancer, regardless of surgical approach or treatment volumes.(PL 01 – Plenary Session) 1 - A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast ...